Groupe Athena, Inc. Sets Date for First Quarter Financials Release
MUMBAI, India, Sept. 28, 2011 /PRNewswire/ -- Groupe Athena, Inc. (Pink sheets GATA.PK) announced today they will release the first quarter fiscal year 2012 financials after the close of the market on Monday, October 10, 2011 in line with previously issued guidance of $12,000,000 in revenue for the current quarter.
The company also announced they are interviewing accounting firms to audit the current fiscal year financials and prepare the company for listing on the OTC Bulletin Board by the end of the fiscal year ending June 30, 2013 or sooner if possible.
On August 15, 2011 the company announced they have approximately $60 million in customer orders that they are currently processing, and they are expecting this number to increase in the near term. Based on the orders in hand the company expects to be able to convert at least two thirds or approximately $40 million into revenue during the current fiscal year.
As was previously stated, the Indian pharmaceutical industry is increasingly focusing on exports to the United States and GATA is well positioned to help them get their products approved by the FDA for sales in the US. All of these are potential clients and the Company believes it has an advantage over competitors due to the facilities based in India, and their ability to deliver quick feedback to clients that could result in expedited order generation. With recent additions to equipment, the company will continue to take on additional contracts and continue to anticipate further growth.
About Groupe Athena, Inc.
Groupe Athena, Inc. was incorporated in June 2008 and began operations on July 1 of that year. The company is a research and testing organization and helps various pharmaceutical and medical products and devices companies in India and Southeast Asia to get regulatory approvals and facilitate exports of their products to the United States. The Company accomplishes this by assisting clients from concept through development, providing consultation on regulatory requirements, filings and processes.
The company has a research and marketing facility in India that currently employs 15 consultants and marketing personnel and is working toward aggressively expanding its presence in the Indian pharmaceutical industry. The Company's web address is www.groupeathena.com
For more information contact:
Corporate Shareholder Relations, Inc.
Safe Harbor Statement
Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "should," "could," "would," "may" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions -- activities of competitors and the presence of new or additional competition and conditions of equity markets.
SOURCE Groupe Athena, Inc.
More by this Source
Groupe Athena, Inc. Continues Record Revenue Growth With Strongest Quarter To Date
Feb 12, 2013, 07:15 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.